Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

Benzinga Newsdesk www.benzinga.com Neutral 62.8%

Neg 0% Neu 62.8% Pos 0%

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.